As part of BICO, the world’s leading bioconvergence company, we offer premium bioinks, bioprinters and services that enable critical breakthroughs in 3D cell culturing, tissue engineering and drug development.
By releasing the first universal bioink in 2016, we democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into the thriving $1 billion industry it is today. Our
best-in-class bioinks, bioprinters, software and services are being used by the foremost academics and R&D labs and have enabled critical breakthroughs in a wide range of applications from 3D cell culturing to tissue engineering to drug development. CELLINK is dedicated to taking the on-demand biofabrication of human organs and tissues to the next level, in line with BICO’s vision to leverage bioconvergence in the life sciences and create the future of medicine.
CELLINK’s products are trusted by more than 1,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications.